Tumor-infiltrating lymphocytes in triple-negative and HER2-positive breast cancer: a current analysis
DOI:
https://doi.org/10.29289/2594539420240018Palavras-chave:
Breast cancer, neoadjuvant chemotherapy, tumor-infiltrating lymphocyte, immunohistochemistryResumo
Introduction: The assessment of tumor-infiltrating lymphocytes in breast cancer is strengthened as evidence points to the clinical relevance of this immunological biomarker, especially in triple-negative and HER2-positive subtypes.
Objectives: To evaluate the prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative and HER2-positive breast cancer subtypes, especially their association with pathological complete response and survival.
Methods: A cross-sectional study was conducted at the Liga Norte Riograndense Contra o Câncer, Natal, Brazil, which included patients who underwent neoadjuvant chemotherapy from June 2013 to June 2018, in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, obtaining a sample of 216 patients. Results: There was no statistically significant difference between the variables tumor-infiltrating lymphocytes (mild, moderate, and intense) and overall survival (p=0.52). It was observed that patients with intense tumor-infiltrating lymphocytes had a 100% five-year survival rate, although this data was not statistically significant. Variables such as the presence of metastasis (p=0.0024), clinical staging (p<0.0001), and local recurrence (p<0.0001) impacted overall survival. Conclusions: In this study, no association was demonstrated between the concentration of tumor-infiltrating lymphocytes and prognosis (overall and disease-free survival).
Downloads
Referências
1. Global Cancer Observatory [Internet]. Iarc.fr. 2018 [acesso em 13 maio 2023]. Disponível em: https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf
2. Instituto Nacional do Câncer. Câncer de mama [Internet] [acesso em 12 junho 2023]. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/mama
3. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next Generation. Cell. 2011;144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013
4. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-71. https://doi.org/10.1093/annonc/mdu450
5. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949-55. https://doi.org/10.1200/JCO.2010.30.5037
6. Sun GY, Zhang J, Wang BZ, Jing H, Fang H, Tang Y, et al. The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I–III triple-negative breast cancer. Br J Cancer. 2023;128(11):2044-53. https://doi.org/10.1038/s41416-023-02218-w
7. Seo A, Lee H, Kim E, Kim HC, Moon Kyoo Jang, Lee H, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705-13. https://doi.org/10.1038/bjc.2013.634
8. Almendro V, Kim HJ, Cheng YK, Gonen M, Itzkovitz S, Argani P, et al. Genetic and Phenotypic Diversity in Breast Tumor Metastases. Cancer Res. 2014;74(5):1338-48. https://doi.org/10.1158/0008-5472.CAN-13-2357-T
9. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446-52. https://doi.org/10.1093/jnci/djp335
10. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-7. https://doi.org/10.1200/JCO.2011.41.0902
11. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544-50. https://doi.org/10.1093/annonc/mdu112
12. Perez EA, Thompson E, Ballman KV, Anderson SB, Asmann YW, Kalari KR, et al. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 2015;33(7):701-8. https://doi.org/10.1200/JCO.2014.57.6298
13. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast Cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15(6):593-602. https://doi.org/10.1111/j.1524-4741.2009.00822.x
14. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59. https://doi.org/10.1186/s40425-016-0165-6
15. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983-91. https://doi.org/10.1200/JCO.2014.58.1967
16. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40-50. https://doi.org/10.1016/S1470-2045(17)30904-X
17. Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C, et al. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Eur J Cancer. 2019;118:41-8. https://doi.org/10.1016/j.ejca.2019.05.014
18. Kawajiri H, Takashima T, Naoki Aomatsu, Kashiwagi S, Noda S, Onoda N, et al. Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer. Oncol Lett. 2014;7(3):663-8. https://doi.org/10.3892/ol.2014.1792
19. Huang M, O’Shaughnessy J, Zhao J, Haiderali A, Cortés J, Ramsey SD, et al. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis. Cancer Res. 2020;80(24):5427-34. https://doi.org/10.1158/0008-5472.CAN-20-1792
20. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13-21. https://doi.org/10.1200/JCO.2014.57.0572
21. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al: Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810-21. https://doi.org/10.1056/NEJMoa1910549
22. Abreu E de, Koifman S. Fatores prognósticos no câncer da mama feminina. Rev Bras Cancerol. 2020;48(1):113-31. https://doi.org/10.32635/2176-9745.RBC.2002v48n1.2270
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Michelle Albano Ferreira, Fábio Medeiros de Azevedo, Waleria Pinper, Kleyton Santos de Medeiros, Juliana Lopes de Aguiar Araújo , Diana Taissa Sampaio Marinho Navarro
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
